All In Biotech

Drug Trial Radar · NCT05712356

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors (BOLSTER)

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

66

Actual

Start

May 13, 2023

Primary completion

Apr 5, 2026

Study completion Apr 5, 2026

Sponsor

Lead sponsor
Lisata Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untreated cholangiocarcinoma or those that have progressed after first-line treatment for cholangiocarcinoma. The main questions it aims to answer are: * is the new drug plus standard treatment safe and tolerable * is the new drug plus standard treatment more effective than standard treatment

Conditions

  • Cholangiocarcinoma
  • Gallbladder Cancer
  • Gallbladder Carcinoma
  • Intrahepatic Cholangiocarcinoma
  • Extrahepatic Cholangiocarcinoma
  • Bile Duct Cancer
  • Gall Bladder Cancer
  • Gall Bladder Carcinoma

Interventions

  • certepetideDrug

    LSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given

  • DurvalumabDrug

    1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles

  • CisplatinDrug

    cisplatin 25 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles

  • GemcitabineDrug

    gemcitabine 1000 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles

  • FOLFOX regimenDrug

    The following will be given every 14 days: * oxaliplatin 85 mg/m² and l-folinic acid 200 mg/m² or d,l-folinic acid 400 mg/m² concurrently, as a 2-hour IV infusion * fluorouracil (5-FU) 400 mg/m² will be given as an IV bolus over 5 minutes * fluorouracil (5-FU) 2400 mg/m² will be administered over 46 hours (via home-infusion pump)

  • PlaceboDrug

    Placebo given as a slow IV push over 1 minute when standard treatment(s) are given

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Experiencing Any Adverse EventTime frame: From time of consent until 30 days after treatment discontinuation, up to 18 months

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • University of Arizona Cancer Center

    Tucson, Arizona

  • Moffitt Cancer Center

    Tampa, Florida

  • Alliance for Multispecialty Research

    Merriam, Kansas

  • University of Kansas Cancer Center

    Westwood, Kansas

  • University of Kentucky Medical Center

    Lexington, Kentucky

  • Norton Cancer Institute, Downtown

    Louisville, Kentucky

  • Norton Cancer Institute, Audubon

    Louisville, Kentucky

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Northwell Health - Zuckerberg Cancer Center

    Lake Success, New York

  • Stony Brook Cancer Center

    Stony Brook, New York

  • FirstHealth of the Carolinas, Inc.

    Pinehurst, North Carolina

  • Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center

    Cincinnati, Ohio

  • Spartanburg Medical Center

    Spartanburg, South Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Inova Schar Cancer Institute

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.